Explore

Streams

Products

About Index

Index

By TNW

Tekla Capital Management

3125

Tekla Capital Management

Follow us

Also headquartered in Boston

Terms of Service Privacy Policy Cookie Statement API Integrations Plans & Pricing

Built with ❤︎ by Datalicious ©2019
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

News

Investments 8

Portfolio

Portfolio Tracker

Add info

$113,800,000 IPO

Biopharma firm Atreca goes public

Pfizer Acquires Clinical-Stage Biotech Company Therachon, for Up To $810M

Swiss startup Oculis secures €13.8M funding to treat ophthalmic diseases

$15,711,870 Venture capital (Series B)

,

Oculis Raises CHF15.5M in Extension of Series B Financing

$80,000,000 Venture capital

Milestone Pharmaceuticals Raises $80M in Equity Funding

Funding Health

$125,000,000 Venture capital (Series C)

, ,

Atreca Raises $125M in Series C Funding

Funding

$60,000,000 Venture capital (Series B)

Biotech Company Therachon Raises $60M Mezzanine Financing

Funding Health

$20,000,000 Venture capital (Series B)

BioClin Therapeutics Raises $20M; Completes $50M Series B Financing

Funding Health

| Oculis nabs $20.3 mln Series B

Funding Health

$20,300,000 Venture capital (Series B)

,

Oculis raises $20.3m Series B round to advance treatment for Ophthalmic Diseases

Funding Health

$35,000,000 Venture capital (Series B)

,

Atreca raises $35 mln Series B co-led by Wellington

Funding

$75,000,000 IPO

With $75M Haul, Ovid Continues Flurry of Biotech IPOs

Health Science

$30,000,000 Venture capital (Series B)

,

BioClin Therapeutics inks $30 mln Series B

Messaging Funding Data leaks

$5,000,000 Venture capital (Series A)

Therachon Appoints Luca Santarelli, M.D., as Chief Executive Officer and Extends Series A Financing

Venture capital (Series A)

Oculis Pharma raises Series A led by Brunnur Ventures and Silfurberg

Health Funding

$35,000,000 Venture capital (Series A)

Therachon Secures $35 Million Financing | Business Wire

$75,000,000 Venture capital (Series B)

Ex-Teva CEO's Brain Disease Startup, Ovid, Bags $75M From Crossovers

Health Funding